MLH1 Antibody - #DF3621
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# DF3621, RRID:AB_2835993.
折りたたみ／展開
COCA 2; COCA2; DNA mismatch repair protein Mlh1; FCC 2; FCC2; hMLH 1; hMLH1; HNPCC 2; HNPCC; HNPCC2; MGC5172; MLH 1; MLH1; MLH1_HUMAN; MutL homolog 1 (E. coli); MutL homolog 1; MutL homolog 1 colon cancer nonpolyposis type 2; MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli); MutL protein homolog 1; MutL, E. coli, homolog of, 1;
免疫原
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
- P40692 MLH1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGEALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNQGTQITVEDLFYNIATRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRSIFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLFINHRLVESTSLRKAIETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKLLGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQKLDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNQSLEGDTTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLSLQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC
種類予測
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - P40692 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| S2 | Acetylation | Uniprot | |
| S2 | Phosphorylation | Uniprot | |
| K33 | Ubiquitination | Uniprot | |
| K57 | Ubiquitination | Uniprot | |
| K70 | Ubiquitination | Uniprot | |
| K84 | Ubiquitination | Uniprot | |
| S87 | Phosphorylation | Uniprot | |
| K123 | Ubiquitination | Uniprot | |
| K134 | Ubiquitination | Uniprot | |
| K140 | Ubiquitination | Uniprot | |
| K164 | Ubiquitination | Uniprot | |
| K167 | Ubiquitination | Uniprot | |
| K175 | Ubiquitination | Uniprot | |
| Y183 | Phosphorylation | Uniprot | |
| K196 | Ubiquitination | Uniprot | |
| T212 | Phosphorylation | Uniprot | |
| K236 | Ubiquitination | Uniprot | |
| T288 | Phosphorylation | Uniprot | |
| Y293 | Phosphorylation | Uniprot | |
| S295 | Phosphorylation | Uniprot | |
| K333 | Ubiquitination | Uniprot | |
| S370 | Phosphorylation | Uniprot | |
| K377 | Ubiquitination | Uniprot | |
| Y379 | Phosphorylation | Uniprot | |
| T386 | Phosphorylation | Uniprot | |
| S388 | Phosphorylation | Uniprot | |
| K392 | Sumoylation | Uniprot | |
| K392 | Ubiquitination | Uniprot | |
| K402 | Acetylation | Uniprot | |
| K402 | Ubiquitination | Uniprot | |
| S406 | Phosphorylation | Q13315 (ATM) , Q13535 (ATR) | Uniprot |
| K416 | Sumoylation | Uniprot | |
| K416 | Ubiquitination | Uniprot | |
| K443 | Acetylation | Uniprot | |
| K443 | Ubiquitination | Uniprot | |
| S446 | Phosphorylation | Uniprot | |
| K453 | Ubiquitination | Uniprot | |
| S459 | Phosphorylation | Uniprot | |
| K461 | Acetylation | Uniprot | |
| S467 | Phosphorylation | Uniprot | |
| S477 | Phosphorylation | Uniprot | |
| S486 | Phosphorylation | Uniprot | |
| K488 | Ubiquitination | Uniprot | |
| T495 | Phosphorylation | Uniprot | |
| S508 | Phosphorylation | Uniprot | |
| K688 | Ubiquitination | Uniprot | |
| K732 | Ubiquitination | Uniprot | |
| K751 | Ubiquitination | Uniprot |
研究背景
Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
Nucleus. Chromosome.
Note: Recruited to chromatin in a MCM9-dependent manner.
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
Component of the DNA mismatch repair (MMR) complex composed at least of MSH2, MSH3, MSH6, PMS1 and MLH1. Heterodimer of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with MCM9; the interaction recruits MLH1 to chromatin. Interacts MCM8. Interacts with PMS2. Interacts with MBD4. Interacts with EXO1. Interacts with MTMR15/FAN1.
Belongs to the DNA mismatch repair MutL/HexB family.
研究領域
· Genetic Information Processing > Replication and repair > Mismatch repair.
· Genetic Information Processing > Replication and repair > Fanconi anemia pathway.
· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.